{
    "pmcid": "8730734",
    "qa_pairs": {
        "How can nanobodies be engineered to enhance their neutralization potency against SARS-CoV-2?": [
            "By creating multivalent forms to increase avidity.",
            "By reducing their size to improve tissue penetration.",
            "By targeting only a single epitope on the spike protein.",
            "By decreasing their binding affinity to avoid immune detection."
        ],
        "What advantage do nanobodies have over conventional antibodies in terms of binding?": [
            "They can bind cryptic epitopes inaccessible to conventional antibodies.",
            "They have a larger size that allows for more extensive binding.",
            "They can only bind to the RBD of the spike protein.",
            "They require multimerization to achieve effective binding."
        ],
        "What is a potential application of nanobodies in COVID-19 treatment?": [
            "Inhalation therapies for direct delivery to the respiratory tract.",
            "Oral vaccines to stimulate systemic immunity.",
            "Topical creams for skin protection against the virus.",
            "Intravenous fluids to enhance hydration."
        ],
        "What is one mechanism by which nanobodies can neutralize SARS-CoV-2?": [
            "By inducing conformational changes in the spike protein.",
            "By enhancing the spike protein's ability to bind ACE2.",
            "By increasing the spike protein's stability.",
            "By promoting viral entry into host cells."
        ],
        "What is the primary target for neutralizing antibodies in the SARS-CoV-2 spike protein?": [
            "The receptor-binding domain (RBD) that targets the ACE2 receptor.",
            "The N-terminal domain (NTD) that targets the ACE2 receptor.",
            "The S2 subunit that facilitates membrane fusion.",
            "The furin cleavage site that activates the spike protein."
        ]
    }
}